Enzyme replacement therapy for mucopolysaccharidosis type IV (Morquio syndrome)

To assess the effectiveness, safety and appropriate dose regimen of ERT in people with MPS IV A.
To determine whether evidence from NRSIs (which potentially offers longer follow-ups) can contribute to the ERT efficacy evidence-base, and to determine the potential need for additional RCT evidence.
To consolidate recommendations for the design of future clinical trials.

This is a protocol.

Health topics:

Child health > Genetic disorders > Inborn errors of metabolism

Published:

12 March 2018

Authors:

Shemesh E, Deroma L, Hendriksz CJ, Hollak C, Krishan A

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Shemesh E, Deroma L, Hendriksz CJ, Hollak C, Krishan A. Enzyme replacement therapy for mucopolysaccharidosis type IV (Morquio syndrome). Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD012961. DOI: 10.1002/14651858.CD012961